... PFS(Progression-free surial):无进展生存率 DFS(disease-free surial):无病生存率 TTP(time to progression):肿瘤进展时间 ...
基于134个网页-相关网页
...导治疗可使整体缓解率和完全缓解率均得到提高,且利妥昔单抗的维持治疗能大大提高中位无进展生存率(progression-free survival,PFS)和整体生存率。
基于40个网页-相关网页
·2,447,543篇论文数据,部分数据来源于NoteExpress
共同的初级终点指标为总生存率和无进展生存率。
Coprimary end points were rates of overall and progression-free survival.
因此,替代终点如反应率和无进展生存率被普遍接受,尽管各方意识到风险所在。
Thus, surrogate endpoints like response rate and progression-free survival are commonly accepted, although all parties involved realize the risk involved.
在确诊时的转化预示相对较好的预后,5年无进展生存率和总生存率分别达到66%和88%。
Transformation at the time of diagnosis portends a more favorable prognosis with 5-year PFS and OS rates of 66% and 88%, respectively.
应用推荐